Non-invasive routes for insulin administration: Current state and perspectives

Expert Opinion on Drug Delivery

Volumn 3, Issue 6, 2006, Pages 763-770

  González, Claudio ^a   Kanevsky, Diego ^b   De Marco, Rubén ^c   Di Girolamo, Guillermo ^d,e   Santoro, Silvina ^e  

^a CEMIC   (Argentina)

^b NOVO NORDISK A S   (Denmark)

^c UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^d FAVALORO UNIVERSITY   (Argentina)

^e UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Diabetes therapy; Nasal insulin; Oral insulin; Pulmonary insulin

Indexed keywords

ANTIDIABETIC AGENT; CHITOSAN; EDETIC ACID; GLUCOSE; HEXYL INSULIN MONOCONJUGATE 2; INSULIN; INSULIN ASPART; INSULIN LISPRO; INSULIN PLUS FUMARYL; ISOPHANE INSULIN; LONG ACTING INSULIN; ORAL ANTIDIABETIC AGENT; PLACEBO; POLYACRYLIC ACID; RECOMBINANT HUMAN INSULIN; SHORT ACTING DRUG; UNCLASSIFIED DRUG;

AEROSOL; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; DRUG TOLERABILITY; DRY POWDER; HUMAN; HYPOGLYCEMIA; INHALER; INJECTION SITE PAIN; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT COMPLIANCE; PATIENT SATISFACTION; REVIEW; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT; WHEEZING;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 33751251021     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.3.6.763     Document Type: Review

References (43)

1. THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The effect of intensive treatment of diabetes in the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. (1993) 329:977-1036.
2. SHICHIRI M, KISHIKAWA H, OHKUBO Y et al.: Long-term results of the Kumamoto Study on optimal diabetes control in Type 2 diabetic patients. Diabetes Care (2000) 23(Suppl. 2):B21-B29.
3. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33) Lancet (1998) 352:837-853.
4. BOLLI GB, MARCHI RD, PARK GD et al.: Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia (1999) 42:1151-1167.
5. Insulin pharmacology: In: Textbook of Diabetes (3rd edn). Pickup J, Williams G (Eds), Blackwell Publishing, Oxford, UK (2003):8-11.
6. VON HEUBNER W, DE JONGH SE, LAQUER E: Uber inhalation von insulin. Klin. Wochenschrift (1924) 51:2342-2343.
7. HEINEMANN L: Alternative delivery routes: inhaled insulin. Diabetes Nutr. Metab. (2002) 15(6):417-422.
8. MANDAL TK: Inhaled insulin for diabetes mellitus. Am. J. Health Syst. Pharm. (2005) 62:1359-1364.
9. KAPITZA C, HEISE T, FISHMAN R et al.: Impact of particle size and aerosolization time on the metabolic effect of inhaled insulin aerosol. Diabetes Technol. Ther. (2004) 6:119-127.
10. WHITE S, BENNETT, DB, CHEU, S et al.: EXUBERA®: Pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol. Ther. (2005) 7:896-906.
11. SKYLER J: Pulmonary insulin update. Diabetes Technol. Ther. (2005) 7:834-839.
12. HARSCH IA: Inhaled insulins. Their potential in the treatment of diabetes mellitus. Treat. Endocrinol. (2006) 4(3):131-138.
13. PFUTZNER A, FORST T: Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism. Expert Opin. Drug Deliv. (2005) 2(6):1097-1106.
14. PETERSEN A, PLANK J, BOCK G et al.: Onset of action of inhaled insulin via the AERx® iDMS was faster than subcutaneous human regular insulin aspart. 65th Annual Meeting of Scientific Sessions of American Diabetes Association Annual Meeting, San Diego, CA, USA, 10 - 14 June (2004):479. Abstract.
15. RAVE KM, NOSEK L, DE LA PENA A et al.: Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lyspro. Diabetes Care (2005) 28(10):2400-2405
16. QUATTRIN T, BELANGER A, BOHANNON N et al.: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: results of a 6 month, randomized, comparative trial. Diabetes Care (2004) 27:2622-2627.
17. SKYLER JS, WEINSTOCK RS, RASKIN P: Use of inhaled insulin in a basal/ bolus insulin regimen in Type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care (2005) 28(7):1630-1635.
18. DEFRONZO RA, BERGENSTAL RM, CEFALU WT et al.: Efficacy of inhaled insulin in patients with Type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care (2005) 28(8):1922-1928.
19. ROSENTOCK J, ZINMAN B, MURPHY LJ et al.: Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in Type 2 diabetes: a randomized, controlled trial. Ann. Intern. Med. (2005) 143(8):128.
20. HOLLANDER PA, BLONDE L: Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with Type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care (2004) 27(10):2356-2362
21. HERMANSEN J, RONNEMAA T, PETERSEN A et al.: Intensive therapy with inhaled insulin via the AERx insulin diabetes management system. Diabetes Care (2004) 27:162-167.
22. WEISS S, CHENG S, KOURIDES I et al.: Inhaled insulin provides improved glycemic control in patients with Type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Arch. Intern. Med. (2003) 163:2277-2282.
23. DREYER M: Efficacy and 2 year pulmonary safety of inhaled insulin as adjunctive therapy with metformin or gliblenclamide in Type 2 diabetes patients poorly controlled with oral monotherapy. 40th Annual Meeting European Association Study Diabetes, Munich, Germany 5-9 September (2004):865. Abstract.
24. CRAMER BS, OKIKAWA MS, BELLAIRE MS et al.: Compliance with inhaled insulin treatment using the AERx® Idms insulin diabetes management system. Diabetes Technol. Ther. (2004) 6:800-807.
25. HIMMELMANN A, JENDLE J, PETERSEN A et al.: The impact of smoking on inhaled insulin. Diabetes Care (2003) 26:677.
26. HENRY R, MUDALIAR S, HOWLAND W et al.: Inhaled insulin using the AERx insulin diabetes management system in healthy and asthmatics subjects. Diabetes Care (2003) 26:764.
27. McELDUFF A, MATHER L, KAM P et al.: Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx insulin diabetes management. Br. J. Pharmacol. (2005) 59:546-551.
28. SURGULADZE D, ANDERSON W, FILBEY J et al.: Insulinization of the liver in normal mice by oral delivery of HIM2, a novel modified insulin. Diabetes (2002) 51:1284.
29. CERNEA S, KIDORN M, WOHLGELERNTER J: Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. Clin. Ther. (2004) 26(12):2084-2091.
30. GUEVARA-AGUIRRE J, GUEVARA M, AGUIRRE J et al.: Oral spray insulin in treatment of Type 2 diabetes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study. Diabetes Metab. Res. Rev. (2004) 20(6):472-478.
31. RIGGS SAUTHIER J: Strategies toward the oral delivery of insulin: using molecular modification to solve drug delivery challenges. 227th ACS National Meeting, Anaheim, CA, USA, March 27 - April 1 (2004):MEDI 202. Abstract.
32. WAJCBERG E, MIYASAKI Y, TRIPLITT C et al.: Dose response effect to a single administration of HIM2 in healthy nondiabetic subjects. Diabetes Care (2004) 27(12):2868.
33. CLEMENT S, DANDONA P, STILL J et al.: Oral modified insulin (HIM2) in patients with Type 1 diabetes mellitus: results from a Phase I/II clinical trial. Metab. Clin. Exp. (2004) 53:54.
34. DICOSTANZO C, MOORE M, LAUTZ M et al.: Simulated first-phase insulin release using Humulin or insulin analog HIM2 is associated with prolonged improvement in postprandial glycemia. Am. J. Physiol. Endocrinol. Metab. (2005) 289:E46.
35. KIPNES M, DANDONA M, TRIPATHY D et al.: Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with Type 2 diabetes. Diabetes Care (2003) 26(2):421-426.
36. VARSHOSAZ J: Nasal delivery of insulin using bioadhesive chitosan gels. Drug Delivery (2006) 13:31-38.
37. TOSHINOBU S, HIROSHI K, TOMONOBU N et al.: Effect of aminated gelatin on the nasal absorption of insulin in rats. Biol. Pharm. Bull. (2005) 28:510-514.
38. VERHOEF J, MERKUS F: Drug Absorption Enhancement: Concepts, Possibility, Limitations And Trends. De Boer AG (Ed.), Harwood Academic Publishers, Singapore (1994):119-153.
39. DEGIM Z, DEGIM T, ACARTUK F et al: Rectal and vaginal administration of insulin-chitosan formulations: an experimental study in rabbits. J. Drug Target. (2005), 13:563-572.
40. XUAN B, MCELLAN D, MOORE M et al.: Alternative delivery of insulin via eye drops. Diabetes Technol. Ther. (2005) 5:695-698.
41. KOEVARY SB, NUSSEY J, LAKE S: Accumulation of topically applied porcine insulin in the retina and optic nerve in normal and diabetic rats. Invest. Ophthalmol. Vis. Sci. (2002) 43(3):797-804,
42. PAN Y, ZHAO HY, ZHENG JM: The enhancing effect of electroporation and iontophoresis on the permeation of insulin through human skin. Yao Xue Xue Bao (2002) 37(8):649-652.
43. SELAM J: Inhaled insulin for treatment of diabetes: projects and devices. Expert Opin. Pharmacother. (2003) 4:1373-1377.